The American Society of Clinical Oncology (ASCO) and Association of Cancer Care Centers (ACCC) announced on July 21 a new collaboration to foster participation in cancer treatment trials to more fully reflect the diversity of people at risk for or living with cancer. Read announcement.
The joint ASCO-ACCC initiative is designed to identify and implement novel strategies and practical solutions to increase clinical trial participation of racial and ethnic minority populations that continue to be under-represented in cancer research when compared with their percentages in the overall population of patients with cancer.
ASCO-ACCC Request for Ideas (RFI)
The ASCO-ACCC Request for Ideas (RFI) seeks novel strategies and practical solutions to increase participation of under-represented racial and ethnic populations in cancer treatment trials. The ASCO-ACCC Steering Group will review and select ideas that may be modified, combined, implemented, and evaluated by ASCO and ACCC. The ideas submitted may be implemented and evaluated through the ASCO Targeted Agent and Profiling Utilization Registry (TAPURTM) Study, for example.
Criteria used to review and prioritize proposed ideas will include the potential to address racial and ethnic disparities in cancer treatment trials, replicability of the strategy, and indications that the submitter has demonstrated a commitment to equitable cancer care, among others. Individuals who submit ideas will be given an opportunity to work on the idea implementation, if interested.
The RFI is open for participation now through August 24, 2020. Learn more.
Posted 7/24/2020
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
